PerkinElmer, Inc. (NYSE:PKI) Director Patrick J. Sullivan sold 6,628 shares of the business’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $62.59, for a total value of $414,846.52. Following the completion of the transaction, the director now directly owns 42,951 shares of the company’s stock, valued at $2,688,303.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

PerkinElmer, Inc. (NYSE:PKI) traded down 0.35% during mid-day trading on Tuesday, reaching $62.54. The company’s stock had a trading volume of 706,948 shares. The firm has a 50 day moving average price of $59.06 and a 200 day moving average price of $54.67. The company has a market cap of $6.89 billion, a price-to-earnings ratio of 30.49 and a beta of 0.80. PerkinElmer, Inc. has a 52-week low of $45.35 and a 52-week high of $62.92.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, May 4th. The medical research company reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.01. PerkinElmer had a net margin of 10.52% and a return on equity of 14.26%. The firm had revenue of $514.12 million for the quarter, compared to analysts’ expectations of $506.81 million. During the same quarter in the prior year, the company posted $0.50 earnings per share. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. Equities research analysts anticipate that PerkinElmer, Inc. will post $2.86 earnings per share for the current year.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 10th. Stockholders of record on Friday, July 21st will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Wednesday, July 19th. PerkinElmer’s payout ratio is 13.15%.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/16/insider-selling-perkinelmer-inc-pki-director-sells-6628-shares-of-stock.html.

Large investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. boosted its stake in PerkinElmer by 28.1% in the first quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock worth $115,000 after buying an additional 434 shares during the last quarter. Twin Tree Management LP purchased a new stake in PerkinElmer during the first quarter worth approximately $122,000. Acrospire Investment Management LLC boosted its stake in PerkinElmer by 37.5% in the third quarter. Acrospire Investment Management LLC now owns 2,200 shares of the medical research company’s stock worth $123,000 after buying an additional 600 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in PerkinElmer during the first quarter worth approximately $152,000. Finally, Federated Investors Inc. PA boosted its stake in PerkinElmer by 158.4% in the fourth quarter. Federated Investors Inc. PA now owns 2,997 shares of the medical research company’s stock worth $156,000 after buying an additional 1,837 shares during the last quarter. Hedge funds and other institutional investors own 89.82% of the company’s stock.

PKI has been the topic of a number of research reports. Bank of America Corp lowered PerkinElmer from a “neutral” rating to an “underperform” rating and set a $48.00 price target on the stock. in a report on Friday, February 3rd. BTIG Research restated a “hold” rating on shares of PerkinElmer in a report on Sunday, February 5th. Janney Montgomery Scott upgraded PerkinElmer from a “neutral” rating to a “buy” rating in a report on Monday, March 27th. Cantor Fitzgerald lowered PerkinElmer from an “overweight” rating to a “neutral” rating and set a $60.00 price target on the stock. in a report on Wednesday, April 19th. Finally, Deutsche Bank AG restated a “hold” rating and issued a $55.00 price target on shares of PerkinElmer in a report on Wednesday, January 18th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $57.30.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

5 Day Chart for NYSE:PKI

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.